| Name | Title | Contact Details |
|---|
eMed offers you the first FDA-authorized, virtually guided, at-home COVID-19 rapid antigen test with automated results reporting.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Cianna Medical Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Aliso Viejo, CA. To find more information about Cianna Medical Inc, please visit www.ciannamedical.com
Ōmcare is a digital health company that aims to change the way the world cares by extending the reach of caregivers, increasing medication adherence, and improving treatment outcomes through the power of remote care and two-way video technology. By partnering with pharmacies, payers, providers, and family caregivers, Ōmcare strives to help people live healthier, more vibrant, independent lives and reduce healthcare cost. Ōmcare`s first product is called the Ōmcare Home Health Hub - a web-enabled platform that dispenses medication and provides two-way, audiovisual confirmation of medication adherence while facilitating social interaction and remote telehealth care. Ōmcare exists due to the rapidly aging population; high rate of medication nonadherence; a shortage of family and professional caregivers; continued increase in health care costs; consumer preference for in-home care and aging in place; changing reimbursement for home care services; and advancements remote monitoring and wearable technology.
TytoCare Ltd. is a consumer-focused telehealth company, offering state-of-the-art, patented devices and platform that empower anyone, anywhere and anytime to perform a variety of medical examinations and seamlessly consult with a clinician. The company was founded by Dedi Gilad, Ofer Tzadik and industry experts in 2012. Investors include OrbiMed Advisors, Walgreens, Cambia Health Solutions, Fosun Pharma, LionBird, Teuza VC and others.